Notis McConarty Edward Sells 1,194 Shares of Johnson & Johnson (NYSE:JNJ)

Notis McConarty Edward trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 37,203 shares of the company’s stock after selling 1,194 shares during the period. Johnson & Johnson comprises 2.6% of Notis McConarty Edward’s investment portfolio, making the stock its 14th biggest position. Notis McConarty Edward’s holdings in Johnson & Johnson were worth $5,380,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $33,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Bank of America increased their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $153.03 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a fifty day moving average of $159.75 and a 200 day moving average of $155.91. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $368.77 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.29 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.